The most aggressive move in the latest data, as of July 9, 2026, involves Eli Lilly (LLY). Truist Securities pushed its target to $1,370 from $1,281, a significant $89 upward adjustment that signals continued confidence in the drugmaker’s pipeline. This shift stands in contrast to the broader trend seen among its peers, where several major names endured downward revisions.
The week in PT changes
Financials saw a flurry of activity yesterday, with UBS acting as the primary catalyst. The firm adjusted its outlook for four different names in the sector, nudging MetLife (MET) up to $105 from $102 and lifting Aon (AON) to $383 from $360. Perhaps more telling was the move on Chubb (CB), where the target jumped from $340 to $369, even as the implied upside dipped into negative territory. Schwab (SCHW) also received a boost, moving to $122 from $119.
Healthcare, however, remains the epicenter of conflicting sentiment. While LLY saw upward momentum from both Truist and Morgan Stanley—the latter raising its mark to $1,347—other stalwarts faced cuts. Morgan Stanley lowered its target for Regeneron (REGN) by $58, taking it to $730, and trimmed Gilead (GILD) to $166. Meanwhile, JP Morgan lowered its outlook for Pfizer (PFE) to $28 from $30.
Elsewhere, the industrial and materials sectors showed incremental adjustments. Martin Marietta Materials (MLM) saw a modest lift from Citigroup to $737, while Vulcan Materials (VMC) was pulled down slightly by UBS to $349. In the technology space, Palo Alto Networks (PANW) faced a sharp downward revision, with Evercore ISI Group cutting its target by $55 to $320.
| Ticker | Firm | Dir | Prior→Current |
|---|---|---|---|
| LLY | Truist Securities | Up | 1281→1370 |
| PANW | Evercore ISI Group | Down | 375→320 |
| AON | UBS | Up | 360→383 |
| VICI | Morgan Stanley | Down | 38→31 |
What the data does not say
These revisions, found on our price target moves page, reflect the internal modeling of individual analyst teams rather than a collective market mandate. When an analyst lowers a price target, it does not necessarily imply a negative view on the company’s underlying business performance; often, it is a mathematical reaction to shifting interest rate assumptions, peer group valuation multiples, or updated quarterly guidance.
Furthermore, a downward revision—such as the $12 reduction for ConocoPhillips (COP) by UBS—often leaves the company with substantial implied upside, highlighting the gap between current market prices and analyst expectations. Investors should be careful not to conflate a change in a target price with a fundamental change in the thesis for these large-cap equities. These figures represent snapshots in time, calibrated to the specific variables used by each firm, and are not indicators of near-term price direction.